Phase I/II Study of Oral and Intramucosal Ad5CMV-p53 Gene in Patients With Diffuse Premalignant Carcinoma of the Oral Cavity or Oral Pharynx
Last Modified: 8/20/2007  First Published: 6/23/2003
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Prevention
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
MDA-ID-00193 NCI-6053, NCT00064103, 6053
|
|
|
Objectives - Determine the acute toxic effects of Ad5CMV-p53 gene administered as an oral rinse and as an intramucosal injection in patients with diffuse premalignant carcinoma of the oral cavity or oral pharynx.
- Determine the maximum tolerated dose of this drug in these patients.
- Determine the topical transduction efficiency of adenoviral-mediated wild type p53 gene transfer in patients treated with this drug.
- Determine the efficacy of this drug in reversing the histology of oral premalignancies in these patients.
- Determine the distribution of transgenic protein within the area of the premalignant lesion in patients treated with this drug.
Entry Criteria Disease Characteristics:
- Histologically confirmed mild to moderate dysplasia OR severe dysplasia/carcinoma in situ of the oral cavity or oral pharynx
- Clinically evident diffuse premalignant disease, defined by 1 of the following mucosal abnormalities:
- Extension between adjacent organ structures (e.g., lateral tongue, ventral tongue, and the floor of the mouth)
- Extensive surface area, including the entire ventral tongue or floor of the mouth or buccal mucosa, in a velvety "indiscreet" pattern
- Meets 1 of the following criteria:
- Previously treated with conventional treatment (e.g., radiotherapy or surgery) for a prior head and neck malignancy
- Failed biochemoprevention approaches for premalignant disease
- Failed other therapeutic approaches for premalignant disease
- No active squamous cell carcinoma of the head and neck
Prior/Concurrent Therapy:
Biologic therapy - See Disease Characteristics
Chemotherapy - More than 21 days since prior chemotherapy (42 days for mitomycin and nitrosoureas)
- No concurrent systemic chemotherapy
Endocrine therapy - No concurrent prednisone or the equivalent, including corticosteroids of more than 10 mg/day
Radiotherapy - See Disease Characteristics
- More than 3 months since prior radiotherapy involving the lesion selected for this study
- No concurrent radiotherapy
Surgery - See Disease Characteristics
Other - More than 8 weeks since prior investigational agents
- No prior experimental therapy (i.e., oral, systemic, topical, or direct injection) for the lesion selected for treatment in this study
- No other concurrent immunosuppressive therapy
- No other concurrent investigational agents
- No concurrent aspirin dose greater than 175 mg/day
Patient Characteristics:
Age Performance status Life expectancy Hematopoietic - Absolute granulocyte count at least 2,000/mm3
- Platelet count at least 100,000/mm3
Hepatic - Bilirubin no greater than 1.0 mg/dL
Renal - Creatinine no greater than 1.5 mg/dL
Cardiovascular - No hypertension (baseline blood pressure 140/90 mm Hg or higher)
Other - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier contraception during and for 1 year after study participation
- HIV-1 negative
- No known contact with former tissue or organ transplantation recipients or individuals with severe immunodeficiency disease (acquired or congenital) during and for 28 days after study treatment
- No prior malignancy within the past 2 years except nonmelanoma skin cancer or aerodigestive cancer
- No active systemic viral, bacterial, or fungal infections requiring treatment
- No serious concurrent illness that would preclude study compliance and follow-up
- No psychological, familial, sociological, geographical, or other condition that would preclude study compliance and follow-up
Expected Enrollment 51A total of 18-51 patients (18 for phase I and 33 for phase II) will be accrued for this study. Outcomes Primary Outcome(s)Safety at weeks 2-4 and then for 6 months Maximum tolerated dose of Ad5CMV-p53 gene administered as an oral rinse at weeks 2-4 and then for 6 months Transduction and efficiency of treatment as measured by Simon's optimal 2-stage design at weeks 2-4 and then for 6 months
Secondary Outcome(s)Effect of p53 gene transfer on molecular biomarkers of p53 activity reduction as measured by immunohistochemical staining at baseline and during courses 1 and 6
Outline This is an open-label, dose-escalation study of Ad5CMV-p53 gene administered as an oral rinse. Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years. Patients then receive long-term follow-up annually for an additional 10 years.
Trial Contact Information
Trial Lead Organizations M. D. Anderson Cancer Center at University of Texas | | | Gary L. Clayman, MD, DDS, Protocol chair | | | | Scott Lippman, MD, FACP, Protocol co-chair | | Ph: 713-745-5439; 800-392-1611 |
| |
Registry Information | | Official Title | | Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] | | Trial Start Date | | 2006-06-25 | | Registered in ClinicalTrials.gov | | NCT00064103 1 | | Date Submitted to PDQ | | 2003-05-20 | | Information Last Verified | | 2007-01-25 | | NCI Grant/Contract Number | | CA97007, CA16672 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.
Table of Links
1 | http://clinicaltrials.gov/ct/show/NCT00064103 |
|